[go: up one dir, main page]

MX2009010728A - Compuestos de imidazo[1,2-a]piridina como inhibidores de la tirosina-cinasa repectora. - Google Patents

Compuestos de imidazo[1,2-a]piridina como inhibidores de la tirosina-cinasa repectora.

Info

Publication number
MX2009010728A
MX2009010728A MX2009010728A MX2009010728A MX2009010728A MX 2009010728 A MX2009010728 A MX 2009010728A MX 2009010728 A MX2009010728 A MX 2009010728A MX 2009010728 A MX2009010728 A MX 2009010728A MX 2009010728 A MX2009010728 A MX 2009010728A
Authority
MX
Mexico
Prior art keywords
receptor tyrosine
imidazo
tyrosine kinase
kinase inhibitors
pyridine compounds
Prior art date
Application number
MX2009010728A
Other languages
English (en)
Inventor
Stephen T Schlachter
James P Rizzi
Qian Zhao
Joseph P Lyssikatos
Nicholas C Kallan
John E Robinson
Shelley Allen
Julie Marie Greschuk
Fredrik P Marmsaeter
Mark C Munson
George T Topalov
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of MX2009010728A publication Critical patent/MX2009010728A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se describen los compuestos de la Fórmula I: en los cuales A, B, R1, R1a, R2, R3, R4, R5 R6, R7 y R8 tienen los significados dados en la especificación, que son inhibidores de la tirosina-cinasa receptora, útiles en el tratamiento de enfermedades mediadas por tirosina-cinasas receptoras de la clase 3 y de la clase 5. Los compuestos particulares de esta invención han sido también encontrados como inhibidores de Pim-1.
MX2009010728A 2007-04-03 2008-03-27 Compuestos de imidazo[1,2-a]piridina como inhibidores de la tirosina-cinasa repectora. MX2009010728A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90985707P 2007-04-03 2007-04-03
PCT/US2008/058395 WO2008124323A1 (en) 2007-04-03 2008-03-27 Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2009010728A true MX2009010728A (es) 2009-10-26

Family

ID=39539641

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009010728A MX2009010728A (es) 2007-04-03 2008-03-27 Compuestos de imidazo[1,2-a]piridina como inhibidores de la tirosina-cinasa repectora.

Country Status (25)

Country Link
US (1) US8138181B2 (es)
EP (1) EP2137184B1 (es)
JP (1) JP5374492B2 (es)
KR (1) KR101538179B1 (es)
CN (2) CN103214482B (es)
AU (1) AU2008237507B2 (es)
BR (1) BRPI0809998B8 (es)
CA (1) CA2682981C (es)
CO (1) CO6251377A2 (es)
CY (1) CY1114277T1 (es)
DK (1) DK2137184T3 (es)
ES (1) ES2420113T3 (es)
HR (1) HRP20130660T1 (es)
IL (1) IL201300A0 (es)
MX (1) MX2009010728A (es)
MY (1) MY157724A (es)
NZ (1) NZ580327A (es)
PL (1) PL2137184T3 (es)
PT (1) PT2137184E (es)
RS (1) RS52862B (es)
RU (1) RU2467008C2 (es)
TW (1) TWI429434B (es)
UA (1) UA101611C2 (es)
WO (1) WO2008124323A1 (es)
ZA (1) ZA200907674B (es)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2343298B9 (en) 2005-12-13 2020-05-06 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
CA2672213C (en) 2006-12-22 2016-02-16 Astex Therapeutics Limited Bicyclic amine derivatives as protein tyrosine kinase inhibitors
MX2009006706A (es) 2006-12-22 2009-07-02 Astex Therapeutics Ltd Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
RS53245B2 (sr) 2007-06-13 2022-10-31 Incyte Holdings Corp Soli inhibitora janus kinaze (r)-3-(4-(7h-pirolo(2,3-d) pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropan-nitrila
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
EP2296653B1 (en) 2008-06-03 2016-01-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
CA2952692C (en) 2008-09-22 2020-04-28 Array Biopharma Inc. Substituted imidazo[1,2b]pyridazine compounds
US20110184013A1 (en) * 2008-10-01 2011-07-28 Shelley Allen Imidazo[1,2-a]Pyridine Compounds As Receptor Tyrosine Kinase Inhibitors
PT3372605T (pt) 2008-10-22 2021-12-09 Array Biopharma Inc Compostos de pirazolo[1,5-a]pirimidina substituídos como inibidores de quinase trk
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
HRP20192203T1 (hr) 2009-05-22 2020-03-06 Incyte Holdings Corporation 3-[4-(7h-pirolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]oktan- ili heptan-nitril kao jak inhibitori
WO2010135650A1 (en) 2009-05-22 2010-11-25 Incyte Corporation N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
BR112012010041A2 (pt) 2009-10-30 2016-05-24 Janssen Pharmaceutica Nv derivados de imidazo [1,2-b] piridazina e seu uso como inibidores de pde10
FR2953838B1 (fr) * 2009-12-10 2012-02-24 Sanofi Aventis Derives de 9h-beta-carboline (ou 9h-pyridino[3,4-b]indole) trisubstitues, leur preparation et leur utilisation therapeutique
FR2953837B1 (fr) * 2009-12-10 2012-03-09 Sanofi Aventis Derives 9h-pyridino[3,4-b]indole disubstitues, leur preparation et leur utilisation therapeutique
MY163791A (en) * 2009-12-21 2017-10-31 Array Biopharma Inc SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS cFMS INHIBITORS
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
SI3354652T1 (sl) 2010-03-10 2020-08-31 Incyte Holdings Corporation Derivati piperidin-4-il azetidina kot inhibitorji JAK1
BR112012026948A2 (pt) * 2010-04-28 2019-09-24 Daiichi Sankyo Co Ltd composto, composição farmacêutica, e, métodos para melhorar o metabolismo ósseo, para previnir ou tratar uma doença associada com metabolismo ósseo e para previnir ou tratar osteoporose.
SMT201900203T1 (it) 2010-05-20 2019-05-10 Array Biopharma Inc Composti macrociclici come inibitori di trk chinasi
MY161078A (en) 2010-05-21 2017-04-14 Incyte Holdings Corp Topical formulation for a jak inhibitor
JP5917545B2 (ja) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤としてのシクロブチル置換ピロロピリジンおよびピロロピリミジン誘導体
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
TWI527813B (zh) * 2010-12-13 2016-04-01 亞雷生物製藥股份有限公司 作為III型受體酪胺酸激酶抑制劑之經取代Ｎ－（１Ｈ－吲唑－４－基）咪唑并 ［１，２－ａ］吡啶－３－甲醯胺化合物
US8889704B2 (en) * 2011-02-25 2014-11-18 Array Biopharma Inc. Triazolopyridine compounds as PIM kinase inhibitors
PE20140832A1 (es) 2011-06-20 2014-07-14 Incyte Corp Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
WO2013000924A1 (en) 2011-06-27 2013-01-03 Janssen Pharmaceutica Nv 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES
WO2013005057A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) New compounds
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
CN103214481B (zh) * 2012-01-21 2016-08-03 中国科学院上海药物研究所 新型咪唑并[1,2-a]吡啶类化合物、其制备方法、包含此类化合物的药物组合物及其用途
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
ES2855575T3 (es) 2012-06-26 2021-09-23 Janssen Pharmaceutica Nv Combinaciones que comprenden compuestos de 4-metil-[1,2,4]triazolo[4,3-a]quinoxalina como inhibidores de PDE2 e inhibidores de PDE10 para su uso en el tratamiento de trastornos neurológicos o metabólicos
EP2869822B1 (en) 2012-07-09 2016-09-14 Janssen Pharmaceutica, N.V. Inhibitors of phosphodiesterase 10 enzyme
SG11201503299YA (en) * 2012-09-28 2015-06-29 Univ Vanderbilt Fused heterocyclic compounds as selective bmp inhibitors
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
WO2014078331A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
TWI702057B (zh) 2012-11-15 2020-08-21 美商英塞特控股公司 盧梭利替尼之緩釋性劑型
WO2014110574A1 (en) 2013-01-14 2014-07-17 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
ES2790419T3 (es) 2013-01-15 2020-10-27 Incyte Holdings Corp Los compuestos de tiazolcarboxamidas y piridinacarboxamida útiles como inhibidores de quinasa de PIM
ES2900492T3 (es) 2013-03-06 2022-03-17 Incyte Holdings Corp Procesos y productos intermedios para elaborar un inhibidor de JAK
EP2994142A4 (en) * 2013-05-08 2017-03-29 Colorado Seminary, Which Owns and Operates The University of Denver Antibiotic and anti-parasitic agents that modulate class ii fructose 1,6-bisphosphate aldolase
RS60469B1 (sr) 2013-08-07 2020-07-31 Incyte Corp Dozni oblici sa produženim oslobađanjem za jak1 inhibitor
US9556197B2 (en) 2013-08-23 2017-01-31 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
WO2015153683A1 (en) 2014-04-02 2015-10-08 Intermune, Inc. Anti-fibrotic pyridinones
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
CA2967951C (en) 2014-11-16 2023-11-07 Array Biopharma, Inc. Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
CA3003153A1 (en) 2015-10-26 2017-05-04 Loxo Oncology, Inc. Point mutations in trk inhibitor-resistant cancer and methods relating to the same
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
PH12018502124B1 (en) 2016-04-04 2024-04-12 Loxo Oncology Inc Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
PT3458456T (pt) 2016-05-18 2020-12-07 Array Biopharma Inc Preparação de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidino-1-carboxamida
EP3512834A4 (en) * 2016-09-14 2020-05-06 Vanderbilt University INHIBITION OF BMP SIGNALING, COMPOUNDS, COMPOSITIONS AND USES THEREOF
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
PT3746429T (pt) 2018-01-30 2022-06-20 Incyte Corp Processos para a preparação de (1-(3-fluoro-2-(trifluorometil)isonicotinoíl)piperidin-4-ona)
EP3765460A1 (en) 2018-03-14 2021-01-20 Vanderbilt University Inhibition of bmp signaling, compounds, compositions and uses thereof
EP4424328A3 (en) 2018-03-30 2024-12-04 Incyte Corporation Treatment of hidradenitis suppurativa using jak inhibitors
CN110833554B (zh) * 2018-08-15 2022-03-08 广西梧州制药（集团）股份有限公司 吡唑并嘧啶衍生物在治疗自身免疫性甲状腺疾病的用途
EP4371987B9 (en) 2018-10-31 2025-11-26 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
KR102658602B1 (ko) 2018-10-31 2024-04-19 길리애드 사이언시즈, 인코포레이티드 Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2022031928A1 (en) * 2020-08-05 2022-02-10 The General Hospital Corporation Salt inducible kinase inhibitors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
BR0109056A (pt) * 2000-03-06 2003-06-03 Warner Lambert Co Inibidores da cinase de tirosina de 5-alquilpirido[2,3-d]pirimidinas
ATE300540T1 (de) 2000-04-27 2005-08-15 Yamanouchi Pharma Co Ltd Imidazopyridin-derivate
AP1666A (en) * 2000-09-11 2006-09-29 Chiron Corp Quinolinone derivatives as tyrosine kinase inhibitors.
SE0100567D0 (sv) 2001-02-20 2001-02-20 Astrazeneca Ab Compounds
US7074801B1 (en) 2001-04-26 2006-07-11 Eisai Co., Ltd. Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof
DE60318198T2 (de) 2002-05-02 2008-12-04 Merck & Co., Inc. Tyrosinkinase-hemmer
PA8580301A1 (es) 2002-08-28 2005-05-24 Pfizer Prod Inc Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
DE10246890A1 (de) * 2002-10-08 2004-04-22 Grünenthal GmbH Substituierte C-Imidazo[1,2-alpyridin-3-yl-methylamine
PA8595001A1 (es) 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
US20050256309A1 (en) * 2004-05-12 2005-11-17 Altenbach Robert J Tri-and bi-cyclic heteroaryl histamine-3 receptor ligands
US7205316B2 (en) * 2004-05-12 2007-04-17 Abbott Laboratories Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands
CN101083985A (zh) 2004-09-21 2007-12-05 幸讬制药公司 用于炎症及免疫相关用途的化合物
EP1799670A1 (en) 2004-10-07 2007-06-27 Pfizer Products Inc. Benzoimidazole derivatives useful as antiproliferative agents
CA2644143C (en) 2006-04-05 2013-10-01 Novartis Ag Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer
US20100144751A1 (en) * 2007-03-28 2010-06-10 Array Biopharma Inc. IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS
US20110184013A1 (en) * 2008-10-01 2011-07-28 Shelley Allen Imidazo[1,2-a]Pyridine Compounds As Receptor Tyrosine Kinase Inhibitors

Also Published As

Publication number Publication date
NZ580327A (en) 2012-02-24
KR101538179B1 (ko) 2015-07-20
AU2008237507B2 (en) 2014-03-20
UA101611C2 (ru) 2013-04-25
EP2137184B1 (en) 2013-05-08
ZA200907674B (en) 2013-04-24
US8138181B2 (en) 2012-03-20
HK1140200A1 (en) 2010-10-08
RS52862B (sr) 2013-12-31
TW200900063A (en) 2009-01-01
CO6251377A2 (es) 2011-02-21
HRP20130660T1 (en) 2013-08-31
CN103214482B (zh) 2016-06-29
JP2010523576A (ja) 2010-07-15
CA2682981C (en) 2015-11-17
BRPI0809998A2 (pt) 2014-10-14
BRPI0809998B1 (pt) 2019-12-31
EP2137184A1 (en) 2009-12-30
RU2467008C2 (ru) 2012-11-20
PT2137184E (pt) 2013-08-01
US20100029633A1 (en) 2010-02-04
RU2009140407A (ru) 2011-05-10
CN101679423A (zh) 2010-03-24
AU2008237507A1 (en) 2008-10-16
CY1114277T1 (el) 2016-08-31
ES2420113T3 (es) 2013-08-22
WO2008124323A1 (en) 2008-10-16
IL201300A0 (en) 2010-05-31
KR20090126320A (ko) 2009-12-08
CN103214482A (zh) 2013-07-24
PL2137184T3 (pl) 2013-09-30
MY157724A (en) 2016-07-15
BRPI0809998B8 (pt) 2021-05-25
JP5374492B2 (ja) 2013-12-25
TWI429434B (zh) 2014-03-11
CA2682981A1 (en) 2008-10-16
DK2137184T3 (da) 2013-07-22

Similar Documents

Publication Publication Date Title
MX2009010728A (es) Compuestos de imidazo[1,2-a]piridina como inhibidores de la tirosina-cinasa repectora.
WO2008121687A3 (en) Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
PH12013501754A1 (en) Triazolopyridine compounds as pim kinase inhibitors
MY156727A (en) N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
PE20090506A1 (es) DERIVADOS DE IMIDAZO-[1,2-b]-PIRIDAZIN COMO INHIBIDORES DE ALK5 Y/O ALK4
MY169791A (en) Substituted pyrazolo [1,5-a] pyrimidine compounds as trk kinase inhibitors
MX347917B (es) Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso.
ZA201100526B (en) Triazolo [4,5-d]pyramidine derivatives and their use as purine receptor antagonists
TW201129565A (en) Tricyclic heterocyclic compounds, compositions and methods of use thereof
EA201001242A1 (ru) ПИРРОЛО[2,3-d]ПИРИДИНЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ТИРОЗИНКИНАЗЫ
NZ703111A (en) Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
UA104731C2 (ru) Ингибиторы р38 мар-киназ
TW200740815A (en) P38 MAP kinase inhibitors and methods for using the same
MX2010006748A (es) Pirazolo[1,5-a]pirimidinas utiles como inhibidores de jak2.
IN2014DN07384A (es)
MX2009010037A (es) Aminopirimidinas utiles como inhibidores de cinasas.
MX2009009590A (es) Aminopirimidinas utiles como inhibidores de proteinas cinasas.
WO2011080568A8 (en) Novel pyrimidine compounds as mtor and pi3k inhibitors
MY167575A (en) Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
MX2009011811A (es) Aminopirimidinas utiles como inhibidores de cinasa.
MY150747A (en) Pyrido[2,3-d] pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
WO2007097981A3 (en) Alpha carbolines and uses thereof
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
MX2012002327A (es) Inhibidores de cinasa, formas de profarmaco de los mismos y su uso en terapia.
NO20080418L (no) Pyrido[2,3-D]pyrimidiriderivater, fremgangsmate for fremstilling derav og terapeutisk anvendelse av samme

Legal Events

Date Code Title Description
FG Grant or registration